E Gat
9 Papers
9 Citations
E Gat is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Emmanuel Bachy,Steven Le Gouill,Roberta Di Blasi,Pierre Sesques,Guillaume Manson,Guillaume Cartron,D. Beauvais,L. Roulin,François-Xavier Gros,Marie-Thérèse Rubio,Pierre Bories,Jacques-Olivier Bay,Cristina Castilla Llorente,Sylvain Choquet,Rene-Olivier Casasnovas,Mohamad Mohty,Stéphanie Guidez,Magalie Joris,Michael Loschi,Sylvain Carras,Julie Abraham,Adrien Chauchet,Laurianne Drieu La Rochelle,Bénédicte Deau-Fischer,Olivier Hermine,Thomas Gastinne,Jean-Jacques Tudesq,E Gat,Florence Broussais,Catherine Thieblemont,Roch Houot,Franck Morschhauser +31 more
TL;DR: In this article , axicabtagene ciloleucel and tisagenlecleucel (tisa-cel) were compared in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL).
Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis.
Roberta Di Blasi,Steven Le Gouill,Emmanuel Bachy,Guillaume Cartron,D. Beauvais,Fabien Le Bras,François-Xavier Gros,Sylvain Choquet,Pierre Bories,Pierre Feugier,Olivier Casasnovas,Jacques-Olivier Bay,Mohamad Mohty,Magalie Joris,Thomas Gastinne,Pierre Sesques,Jean-Jacques Tudesq,Laetitia Vercellino,Franck Morschhauser,E Gat,Florence Broussais,Roch Houot,Catherine Thieblemont +22 more
TL;DR: A multicentric analysis confirms the poor outcome of patients relapsing after CAR T-cells, highlighting the need for further strategies dedicated to this population and predictors of OS were high LDH at infusion, time to CAR-T failure
80
•Journal Article
Dental underemployment: a study of uncontrolled dental manpower immigration.
TL;DR: To prevent a significant unemployment rate among dentists and an uncontrolled free market, it is urgently suggested for the benefit of both provider and consumer that the demand for services be increased and additional financing of dental care be made available.
8
Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry
H. S. Bensaber,Emmanuel Bachy,D. Beauvais,Remy Dulery,Thomas Gastinne,Bruno Villemagne,L. Roulin,Etienne Paubelle,Cristina Castilla-Llorente,Thomas Longval,E Gat,Amandine Fayard,Jacques-Olivier Bay,Steven Le Gouill,Roch Houot,Romain Guieze +15 more
TL;DR: In this paper , the authors investigated the efficacy and safety profile of CD19-CAR T-cell therapy for patients with Richter syndrome (RS) in patients with chronic lymphocytic leukemia (CLL).
7
Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry
Gabriel Brisou,Guillaume Cartron,Emmanuel Bachy,Catherine Thieblemont,Cristina Castilla-Llorente,Fabien Le Bras,François-Xavier Gros,Michael Loschi,Roch Houot,Remy Dulery,Fabrice Jardin,Magalie Joris,Choquet Sylvain,Franck Morschhauser,Stéphanie Guidez,Olivier Hermine,Laurianne Drieu La Rochelle,Sylvain Carras,Blandine Guffroy,Pierre Bories,Rene-Olivier Casasnovas,Julie Abraham,Steven Le Gouill,Pascale Cony-Makhoul,E Gat,Benoit Tessoulin +25 more
TL;DR: Axicabtagene ciloleucel (axi-cel) is feasible and safe in real-life for patients with relapsed/refractory large B-cell lymphoma (LBCL) in both transplant and non-transplant eligible patients.
5